What Novo Nordisk actually looks for
Novo Nordisk, headquartered near Copenhagen, Denmark, has been a leader in diabetes care and insulin for decades, but the company's global profile changed dramatically with semaglutide, sold as Ozempic for diabetes and Wegovy for weight management, plus an oral version called Rybelsus. Demand for these GLP-1 drugs has been so intense that Novo Nordisk has repeatedly invested in expanding manufacturing capacity, and the company briefly became the most valuable public company in Europe at points during the GLP-1 boom. Novo Nordisk is majority controlled through the Novo Nordisk Foundation, a structure that shapes a longer-term, less quarter-to-quarter strategic orientation than some purely shareholder-driven competitors, and interviewers may reference this ownership model when discussing how decisions get made. Given the scale of global demand, expect operations and supply chain interviews to focus heavily on manufacturing scale-up and equitable access challenges, since shortages have been a real, publicly discussed issue.
Common questions and how to answer them
How has Novo Nordisk managed manufacturing capacity given the surge in Ozempic and Wegovy demand? Discuss the company's ongoing investment in new production facilities and how it has had to prioritize allocation across diabetes and weight management indications during shortages. How does the Novo Nordisk Foundation's ownership structure influence company strategy? Show awareness that foundation ownership can support longer-term investment horizons compared to companies under more typical shareholder pressure, without overstating how different day-to-day operations actually are. What's your view on the access and affordability challenges around GLP-1 drugs? Answer with a balanced view that acknowledges both the genuine health benefit and the real cost barrier for many patients, since this is a live public policy conversation, not a settled issue. Across all three, acknowledge both the commercial success and the real supply and access challenges around semaglutide, since a one-sided answer misses the genuine tension Novo Nordisk is managing.
How to prepare
Understand semaglutide's role across Ozempic, Wegovy, and Rybelsus, and be ready to discuss why the same active ingredient serves different indications at different doses. Follow recent news on Novo Nordisk's manufacturing capacity expansion, since supply has been a consistent, real operational story rather than a one-time issue. If relevant to your role, understand the Novo Nordisk Foundation's ownership structure and how it differs from a typical public company governance model. Expect operations roles to include scenario questions about allocating limited manufacturing capacity across markets and indications, since supply constraints have been a genuine, recurring operational reality for the company. It also helps to have a point of view on how the company should balance rapid growth with responsible, equitable access to its most in-demand medicines.